Mapping RANKL-and OPG-expressing cells in bone tissue:the bone surface cells as activators of osteoclastogenesis and promoters of the denosumab rebound effect
Bilal M.El-Masri Lars J.Hansen Albert S.Kim Victoria E.Taylor Caitlyn Massarotti Michelle M.McDonald Xiaomeng You Julia F.Charles Jean-Marie Delaisse Thomas L.Andersen Christina M.Andreasen Kaja S.Laursen Viktoria B.Kofod Xenia G.Dahl Malene H.Nielsen Jesper S.Thomsen Annemarie Brüel Mads S.Sørensen
Mapping RANKL-and OPG-expressing cells in bone tissue:the bone surface cells as activators of osteoclastogenesis and promoters of the denosumab rebound effect
Mapping RANKL-and OPG-expressing cells in bone tissue:the bone surface cells as activators of osteoclastogenesis and promoters of the denosumab rebound effect
摘要
引用本文复制引用
Bilal M.El-Masri,Lars J.Hansen,Albert S.Kim,Victoria E.Taylor,Caitlyn Massarotti,Michelle M.McDonald,Xiaomeng You,Julia F.Charles,Jean-Marie Delaisse,Thomas L.Andersen,Christina M.Andreasen,Kaja S.Laursen,Viktoria B.Kofod,Xenia G.Dahl,Malene H.Nielsen,Jesper S.Thomsen,Annemarie Brüel,Mads S.Sørensen..Mapping RANKL-and OPG-expressing cells in bone tissue:the bone surface cells as activators of osteoclastogenesis and promoters of the denosumab rebound effect[J].骨研究(英文版),2024,12(4):912-932,21.基金项目
We thank Søren Harving for providing the investigated human bone specimens,and Birgit MacDonald,Signe Marie Andersen,and Ariel Castro-Martinez for their technical contributions.The study was supported by Odense University Hospital's Fund for Free Research(A5111),the Region of Southern Denmark's Fund for Free Research(A955),and the VELUX Foundations(VELUX25723).The study was supported by the Novo Nordisk Foundation.Amgen Inc provided the OPG:Fc under a material transfer agreement. (A5111)